In 2013, Infinity launched the DUETTS TM ( Du v e lisib T rials in Hema t ologic Malignancie s ) program, a worldwide investigation of duvelisib in blood cancers. As part of the DUETTS program, patient enrollment is ongoing in DYNAMO TM, a Phase 2 monotherapy study designed to evaluate the safety and efficacy of duvelisib in patients with refractory indolent non-Hodgkin lymphoma (iNHL) (ClinicalTrials.gov Identifier NCT01882803), and DUO TM, a Phase 3 monotherapy study designed to evaluate the safety and efficacy of duvelisib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) (NCT02004522). DYNAMO+R TM, a Phase 3 study of duvelisib in combination with rituximab in relapsed follicular lymphoma (NCT02204982), is expected to start in 2014.